Changes to the 340B Program in 2026 – Inflation Reduction Act and More
The federal 340B drug discount program has undergone substantial changes in recent years, with new challenges brought on by manufacturer restrictions and diminishing reimbursement counterbalanced by new opportunities. Perhaps one of the most significant changes are effective on January 1, 2026, when Inflation Reduction Act-mandated negotiated Medicare prices took effect for ten drugs.
This session provides an update on the latest changes to the 340B program, including early experiences with Inflation Reduction Act implementation.
Pharmacy Managers
COOs
CEOs
CFOs
Compliance Officers
Executive Leadership
Understand how Medicare-negotiated pricing will impact 340B program operations and reimbursement
Navigate changes to 340B program compliance
Prepare your organization for the likely evolution of the 340B program.
Jason Reddish
Greg Doggett
Principal
Jason has focused primarily on the 340B Program for the past 13-plus years, representing community health centers, Ryan White HIV/AIDS clinics, and STD program grantees primarily for the past 8 years. His time is split nearly evenly among transactions, compliance, remedial action, and advocacy for covered entity protections at the state and federal level.
Jason earned a B.S. in Physiology / Neurobiology from the University of Maryland and his J.D. from Tulane University. He is licensed in MD, DC, and Ontario.
Counsel
With extensive experience at the crossroads of 340B compliance, pharmacy operations, policy, and advocacy, Greg helps covered entities and other stakeholders navigate an increasingly complex 340B environment. He works with clients to strengthen and modernize their 340B compliance programs, assess and manage risk, and confidently pursue new 340B initiatives. Greg also guides clients through the evolving state and federal policy landscape, crafting tailored strategies and messaging that advance their advocacy goals. In addition, he supports covered entities during government and pharmaceutical manufacturer audits and inquiries, developing clear, effective, and defensible responses.
This is a 60-minute webinar session.
The session was recorded and is available on-demand.
